Blood biomarkers of Alzheimer's disease: findings from proteomics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40094333.
- Also identified by DOI 10.1093/postmj/qgaf039.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alzheimer's disease, the most prevalent cause of dementia, is a worldwide health problem. Proteomics is the systematic study of proteins and peptides to provide comprehensive descriptions. Aiming to obtain a more accurate and convenient clinical diagnosis, researchers are working on blood biomarkers. This review synthesizes findings from previous studies investigating blood biomarkers for Alzheimer's disease using proteomic approaches. We summarized the application of blood proteomics as diagnostic biomarkers and associations with clinical indicators such as neuropsychological performances, Aβ deposition and brain atrophy in Alzheimer's disease, and mild cognitive impairment. In summary, blood proteomics is suggested to be promising in biomarkers of Alzheimer's disease.
Medical subject headings
- Alzheimer Disease
- Proteomics